HEPATITIS MONTHLY, cilt.11, sa.10, ss.835-842, 2011 (SCI-Expanded)
Background: Treatment for chronic hepatitis B (CHB) has improved over the last 10 years mainly due to the development of effective oral antiviral agents [nucleoside/nucleotide analogs (NUCs)].